Payment overview · 2025
General Payments
$648.86
11 reported records · 8 companies
Healthcare provider profile · identity verified
Karen E Genter, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NOVI, MI · NPI 1790407260
Verified facts
What the public records show
CMS Open Payments records show Karen E Genter, FNP received $648.86 in general payments during 2025 across 11 reported records.
ConvaTec Inc. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $202.77 | 31.2% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $179.76 | 27.7% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $140.15 | 21.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.26 | 7.1% | 2 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $32.53 | 5.0% | 1 | 2025 |
| Hollister Incorporated | Unresolved — no canonical attribution shown | $18.01 | 2.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $14.87 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.51 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $648.86 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ESTEEM Normalized: esteem |
Device | ConvaTec Inc. | $202.77 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $179.76 | 2 | 2025 |
Source payment records
|
|||||
| ALLEVYN HEEL 10.5CM X 13.5CM CTN 5 Normalized: allevyn heel 10 5cm x 13 5cm ctn 5 |
Device | Smith+Nephew, Inc. | $140.15 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $140.15 | 1 | 2025 |
Source payment records
|
|||||
| NATURA+ Normalized: natura |
Device | ConvaTec Inc. | $116.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| SenSura Mio Normalized: sensura mio |
Device | COLOPLAST CORP | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| New Image Normalized: new image |
Device | Hollister Incorporated | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 263 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 225 | 52 |
| Potassium Chloride | Potassium Chloride | 171 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 166 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 164 | 34 |
| Omeprazole | Omeprazole | 163 | 40 |
| Eliquis | Apixaban | 156 | 31 |
| Losartan Potassium | Losartan Potassium | 155 | 30 |
| Donepezil Hcl | Donepezil Hcl | 145 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 27 |
| Gabapentin | Gabapentin | 136 | 23 |
| Trazodone Hcl | Trazodone Hcl | 135 | 30 |
| Mirtazapine | Mirtazapine | 126 | 19 |
| Methenamine Hippurate | Methenamine Hippurate | 120 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 25 |
| Metformin Hcl | Metformin Hcl | 113 | 17 |
| Lisinopril | Lisinopril | 109 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 16 |
| Buspirone Hcl | Buspirone Hcl | 73 | suppressed |
| Famotidine | Famotidine | 68 | 13 |
| Carvedilol | Carvedilol | 64 | 13 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 21 |
| Sertraline Hcl | Sertraline Hcl | 53 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 13 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | 16 |
| Jardiance | Empagliflozin | 46 | 11 |
| Simvastatin | Simvastatin | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 35 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Loperamide | Loperamide Hcl | 37 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 32 |
| Baclofen | Baclofen | 36 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 12 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 14 |
| Atenolol | Atenolol | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $648.86 · 11 records | ConvaTec Inc. | ACTIV.A.C., ALLEVYN HEEL 10.5CM X 13.5CM CTN 5, ARISTADA, COLLAGENASE SANTYL, ESTEEM, KISUNLA, LYBALVI, NATURA+, New Image, REXULTI, SenSura Mio | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error